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The 90 kDa heat shock protein (Hsp90) is the core compo-nent of an oligomeric chaperone machine, the function of
which is required for the viability of all eukaryotic cells. Hsp90
functions with a cohort of co-chaperones to facilitate the folding,
activation, and stabilization of numerous client proteins, many of
which have effects in regulating signal transduction pathways.1,2
Among the plethora of Hsp90-dependent clients are proteins that
function in pathways that represent all six hallmarks of cancer.36
Thus, inhibition of Hsp90 function simultaneously incapacitates
multiple client proteins, providing a combinatorial attack on
cellular oncogenic processes. Consequently, Hsp90 has emerged
as an exciting new target for the development of antitumor agents.
Natural product inhibitors of Hsp90 have been discovered
that target binding sites in the N- and C-terminal domains of
Hsp90. Geldanamycin (3) and radicicol, which are produced by
the soil actinomycetes species Streptomyces hygroscopicus and the
mycoparasitic fungus Humicola fuscoatra, respectively, bind to
the ATP binding pocket in Hsp90s N-terminal domain,1,2 while
novobiocin (4), which is produced by Streptomyces spheroides,
inhibits Hsp90 function by binding to Hsp90s C-terminal
domain.7 Other natural products with well-known antitumor
and/or chemopreventive properties, but poorly characterized
mechanisms of action have been discovered to exhibit inhibitory
activity toward Hsp90: epigallocatechin gallate (EGCG),8,9 the
well-known antioxidant found in green tea (Camellia sinensis (L.)
Kuntze); gedunin, a tetranortriterpenoid isolated from the
Indian neem tree (Azadirachta indica A. Juss.; Meliaceae);10,11
celastrol (2), a quinone methide triterpene that is a pharmaco-
logically active compound present in Thunder God Vine root
extracts (Tripterygium wilfordii Hook.f.; Celastraceae);11,12 and
the rotenoid deguelin.13
Derivatives of geldanamycin (3) and other compounds that
target the ATP-binding pocket in Hsp90s N-terminal domain
have entered more than 20 clinical trials for the treatment of
cancer.5,14,15 Clinical complications have arisen in phase II trials
of several Hsp90 inhibitors, with incidences of hepato-, cardio-,
and ocular toxicity having dampened enthusiasm for the clinical
use of Hsp90 inhibitors.5 Consequently, there is an ongoing
search for Hsp90 inhibitors with superior chemotherapeutic
properties for the treatment of cancers.
To this end, we have screened natural product libraries for
compounds that inhibit Hsp90-dependent refolding of ther-
mally denatured firefly luciferase. It was presumed that natural
products represent a fertile territory for the identification of
new Hsp90-inhibitors, as it is reasonable to expect that evolu-
tionary pressures give plants that produce secondary meta-
bolites inhibitory to Hsp90 a competitive advantage, because
such compounds might inhibit the growth and development of
insect pests and other pathogens. Celastrol (2), a knownHsp90
inhibitor,11,12 and ()-gambogic acid (1), a component of
Garcinia hanburyi Hook.f. (Clusiaceae), a species that has been
used medicinally for centuries in southeast Asia, were identified
as inhibitors of luciferase refolding in screens of two natural
product libraries.
Gambogic acid (1), like Hsp90 inhibitors, has antitumor,
antiangiogenic, and antimetastatic activities (reviewed in refs
1618), but a poorly characterized mechanism of action. In
addition, like Hsp90 inhibitors,19 1 has been observed to be
selectively cytotoxic to cancer versus normal cells.20,21 While 1
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ABSTRACT:A high-throughput screening of natural product libraries identified ()-gambogic acid
(1), a component of the exudate of Garcinia harburyi, as a potential Hsp90 inhibitor, in addition to
the known Hsp90 inhibitor celastrol (2). Subsequent testing established that 1 inhibited cell
proliferation, brought about the degradation of Hsp90 client proteins in cultured cells, and induced
the expression of Hsp70 and Hsp90, which are hallmarks of Hsp90 inhibition. Gambogic acid also
disrupted the interaction of Hsp90, Hsp70, and Cdc37 with the heme-regulated eIF2R kinase (HRI,
an Hsp90-dependent client) and blocked the maturation of HRI in vitro. Surface plasmon resonance
spectroscopy indicated that 1 bound to the N-terminal domain of Hsp90 with a low micromolar Kd,
in a manner that was not competitive with the Hsp90 inhibitor geldanamycin (3). Molecular docking
experiments supported the posit that 1 binds Hsp90 at a site distinct from Hsp90s ATP binding
pocket. The data obtained have firmly established 1 as a novel Hsp90 inhibitor and have provided
evidence of a new site that can be targeted for the development of improved Hsp90 inhibitors.
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has been reported to induce apoptosis in cancer cells by binding
to the transferrin receptor,22 the cytotoxic activity of this
compound has also been found to have a transferrin receptor-
independent component.23 A recent publication on gambogic
acid (1) indicates that 1 has recently been subjected to a phase I
clinical trial in the People’s Republic of China as an anticancer
agent.24 Herein, we present the characterization of the Hsp90
inhibitory activity of 1 and compare its mechanism of action to
those of other Hsp90 inhibitors.
’RESULTS AND DISCUSSION
Identification of Gambogic Acid (1) as a Putative Hsp90
Inhibitor from a High-Throughput Screen of Natural Pro-
duct Libraries. Screening of natural product libraries pur-
chased from Microsource and Biomol for compounds that
inhibited Hsp90-dependent refolding of luciferase identified 1
as a potential Hsp90 inhibitor, along with the known Hsp90
inhibitor celastrol (2), among other compounds. Neither
celastrol nor 1 had any direct effect on the activity of native
luciferase. Upon titration of various concentrations of the two
compounds into the refolding assay (Figure 1A), celastrol (2)
and gambogic acid (1) were found to inhibit luciferase
refolding by 50% (IC50) at a concentration of 20 and 2 μM,
respectively.
Gambogic acid (1) has been demonstrated in numerous
studies to inhibit the proliferation of a variety of cancer cell lines
(reviewed in refs 1618). To determine whether antiprolifera-
tive activity of 1 could be correlated with its Hsp90-inhibitory
activity, we examined the effect of varying concentrations of
gambogic acid on the growth/viability of HeLa cells and MCF7
and SK-Br3 breast cancer cell lines. Gambogic acid (1)
inhibited the proliferation of HeLa, MCF7, and SK-Br3 cells
in a concentration-dependent manner (Figure 1B). Growth of
the HeLa, MCF7, and SK-Br3 cells was inhibited by 50%
by treatment with 1.5, 2.0, and 0.8 μM 1, respectively.
The highest concentrations of 1 were cytotoxic, as evidenced
by detachment of a significant number of cells from the surface
of the culture flasks. Thus, the IC50 of 1 for inhibition of cell
proliferation correlated well with its IC50 for the inhibition of
luciferase refolding.
Gambogic Acid (1)-Induced Depletion of Hsp90-Depen-
dent Proteins. Treatment of cultured cells with known Hsp90
inhibitors depletes the cells of Hsp90-dependent proteins in a
time- and concentration-dependent manner. To further charac-
terize 1 as a potential Hsp90 inhibitor, MCF7 and Sk-Br3 cells
were treated with varying concentrations of 1 for 36 h, and
equivalent amounts of protein from cell extracts were Western
blotted for Hsp70 andHsp90 and theHsp90-dependent proteins
Her2, Akt, and Raf-1, using actin as a loading control, geldana-
mycin (3) as a positive control for Hsp90 inhibition, and DMSO
as a negative control. Gambogic acid was observed to deplete
Figure 1. Effect of gambogic acid (1) and celastrol (2) on Hsp90-
dependent luciferase refolding in reticulocyte lysate (A) and effect of 1
on cell proliferation of HeLa cells and MCF7 and SkBr3 breast cancer
cells (B). Experiments were carried out as described in the Experimental
Section.
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MCF7 and Sk-Br3 cells of Her2, Akt, and Raf-1 in a concentra-
tion-dependent fashion (Figure 2), which correlated well with
the IC50 value for inhibition of the proliferation of these cell lines
induced by 1. In addition, 1 induced Hsp90 and Hsp70 expres-
sion, another hallmark of Hsp90 inhibition. This compound had
a similar effect on the levels of Her2, Raf-1, and Akt in HeLa cells
(not shown). These results further support the hypothesis that
the antiproliferative effect of 1 on cancer cell growth is mediated,
at least in part, by its ability to inhibit Hsp90.
Effect of Gambogic Acid (1) on the Association of Hsp90
Chaperone Components with HRI and HRI’s Hsp90-Depen-
dent Maturation. Hsp90 inhibitors have distinct effects on the
conformation and interactions of Hsp90 with co-chaperone
partners and clients.25,26 Geldanamycin (3), an Hsp90 inhibitor
that binds to the ATP pocket in the N-terminal domain of Hsp90
(N-terminal inhibitor), causes Hsp90 to accumulate in com-
plexes that contain intermediate co-chaperone components.
Complexes that form between Hsp90 and kinase clients in the
presence of 3 are salt-labile and lack Cdc37. Molybdate, on the
other hand, inhibits Hsp90 by freezing it in complexes containing
late co-chaperone components. Hsp90-kinase client complexes
formed in the presence of molybdate are stabile at high salt
concentrations (e.g., 0.5 M NaCl) and contain Cdc37. Hsp90
inhibitors that bind to its C-terminal domain (C-terminal
inhibitor), like novobiocin (4), appear to block the interaction
of Hsp90 with most co-chaperones, as well as protein clients.
Celastrol (2), which is thought to bind to the N-terminal domain
of Hsp90 at a site distinct from the ATP binding pocket, inhibits
Hsp90 in a manner distinct from geldanamycin (3) and novo-
biocin (4).25
HRI is a heme-regulated eIF2R kinase that requires Hsp90,
Hsp70, and Cdc37 for its maturation and activation under
heme-deficient conditions.2729 To further characterize the mecha-
nism of action of gambogic acid (1), the effects of 1 on the binding of
Hsp90 chaperone components to HRI were compared to the
effects of the N-terminal inhibitors geldanamycin (3) and
celastrol (2), molybdate, and the C-terminal inhibitors novobio-
cin (4) and coumermycin A1 (5).25 The nonactivatable K199R
mutant of HRI was used in these experiments, as it is unable to
mature and interacts constitutively with Hsp90. In these experi-
ments, the immunoadsorbed samples were washed with low
ionic strength buffer, as it distinguishes between the mechanism
of action of geldanamycin (3) and celastrol (2), which bind to
different sites in the Hsp90s N-terminal domain. In agreement
with results reported previously,3032 (1) geldanamycin (3)
caused the accumulation of Hsp90 in complexes with HRI/
K199R that contained increased amounts of the intermediate co-
chaperone component Hsp70 compared to the DMSO control,
but lacked Cdc37 (Figure 3A, lane 3); (2) molybdate stabilized
the binding of Hsp90 and Cdc37 to HRI/K199R, while not
affecting the interaction of Hsp70 with HRI/K199R (lane 4);
and (3) novobiocin (4) disrupted the interaction of Hsp90,
Hsp70, and Cdc37 with HRI/K199R (lane 6), as did the bivalent
novobiocin-related compound coumermycin A1 (5) (lane 7).
Under similar conditions, celastrol (2) disrupted the binding
of Hsp90, Hsp70, and Cdc37 to HRI (Figure 3A, lane 5), as
did gambogic acid (1) (lane 8). These results indicate that 1
affected the interaction of Hsp90 chaperone components with
HRI/K199R in a manner distinct from geldanamycin (3) and
molybdate.
Subsequently, the effects of 1 on HRI activation were exam-
ined upon incubation in heme-deficient lysate. Hsp90-dependent
maturation and activation ofHRI are accompanied by a change in
its electrophoretic mobility to a more slowly migrating species
(Figure 3B). After 45min of incubation of HRI in heme-deficient
lysate, approximately half of the [35S]HRI had a slower electro-
phoretic mobility upon SDS-PAGE analysis compared to HRI
incubated in heme-replete lysate (lane 2 versus 1). Gambogic
acid (1) inhibited the maturation/activation of HRI in heme-
deficient lysate to an extent similar to the known Hsp90
inhibitors geldanamycin (3), celastrol (2), and molybdate. The
C-terminal Hsp90 inhibitors novobiocin (4) and coumermycin
A1 (5) also inhibited thematuration/activation of HRI, but it was
also apparent that incubation with these compounds reduced the
quantity of [35S]HRI that was present in the samples compared
to the other Hsp90 inhibitors.
To determine whether the decreased recovery of [35S]HRI
was a hallmark of C-terminal Hsp90 inhibitors inducing the
breakdown of HRI or whether it was simply due to less [35S]HRI
being synthesized, aliquots were taken from each sample after
protein synthesis had ceased, prior to the beginning of the
maturational incubation in the presence of the compounds.
Autoradiography of aliquots taken from samples prior to their
maturational incubation indicated that an equivalent amount of
[35S]HRI was present in each sample (Figure 3C, 0 min: upper
panel). Incubation of [35S]HRI in the presence of novobiocin
(4) or coumermycin A1 (5) resulted in a 90% and 80% loss of the
[35S]HRI, respectively (Figure 3C, lanes 6 and 7). However,
significantly less [35S]HRIwas lost upon incubation of samples in
the presence of geldanamycin (3) (0%), molybdate (10%),
celastrol (2) (40%), or 1 (10%) compared to the DMSO control.
A similar effect of novobiocin (4) and coumermycin A1 (5) has
been observed on the stability of Akt generated by TnT in
reticulocyte lysate (not shown). Thus, the effect of Hsp90
Figure 2. Gambogic acid (1)-induced degradation of Hsp90 client
proteins. Compound 1 was incubated with (A) MCF7 and (B) SkBr3
breast cancer cells at concentrations (μM) indicated in the figure.
Gambogic acid (1) was evaluated for its ability to downregulate several
client proteins as described in the Experimental Section. Geldanamycin
(3) (500 nM) and DMSO were used as positive and negative controls,
respectively. Cell extracts were prepared and equivalent amounts of
protein were separated by SDS-PAGE and subsequently Western
blotted for the indicated proteins as described in the Experimental
Section.
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inhibition on the stability of nascent kinases in reticulocyte lysate
appears to be a property that further distinguishes inhibitors of
Hsp90 that bind to its C-terminal domain from inhibitors that
bind to its N-terminal domain.25,26 The absence of an effect of 1
on HRI stability distinguishes its mechanism of action from that
of C-terminal inhibitors. Previously, celastrol (2) was demon-
strated to inhibit Hsp90 by a mechanism that was distinct from
N-terminal inhibitors that bind to the Hsp90s ATP binding
pocket, such as geldanamycin (3).25 The results presented here
indicate that the mechanism of action of 1 is similar to that of
celastrol (2) and distinct from that of 3.
Surface Plasmon Resonance (SPR) Analysis of the Binding
of Gambogic Acid (1) to the N-Terminal Domain of Hsp90.
To determine whether 1 is indeed interacting with the Hsp90s
N-terminal domain, we cloned the N-terminal domain of
Hsp90R (Hsp90NT; amino acids 1241) with a seven-amino-
acid extension at its C-terminus containing a C-terminal Cys
residue. Recombinant Hsp90NT was biotinylated and immobi-
lized onto a neutravidin sensor chip for analysis of the binding of
1 by SPR. Full-length Hsp90 and the C-terminal domain of
Hsp90 (Hsp90CT, amino acids 531732) were immobilized on
sensor chips that were used as positive and negative controls,
respectively. Gambogic acid (1) was observed to bind specifically
to full-length Hsp90 (Figure 4A) andHsp90NT (Figure 4B), but
not to Hsp90CT (data not shown). Analysis of binding and
dissociation kinetics indicated that 1 binds to both Hsp90 and
Hsp90NT with similar association constants (ka), dissociation
constants (kd), and calculated Kd values (9.8 versus 7.6 μM,
respectively, Table 1). Compound 1 was observed also to bind
Hsp90NT in the presence of 20 μM geldanamycin in the analyte
Figure 3. Effect of Hsp90 inhibitors on the interaction of Hsp90 and its co-chaperones with HRI (A), on HRI’s Hsp90-dependent maturation (B), and
on HRI stability (C). (A) [35S]His-tagged HRI/K199R was synthesized by TnT in reticulocyte lysate as described in the Experimental Section. After
10 min, DMSO (4% v/v, lanes 1 and 2), geldanamycin (3, 80 μM, lane 3), sodiummolybdate (20 mM, lane 4), celastrol (2, 100 μM, lane 5), novobiocin
(4, 4.0 mM, lane 6), coumermycin A1 (5, 400 μM, lane 7), or gambogic acid (1, 50 μM, lane 8) was added, followed by an additional 40 min of
incubation. [35S]His-tagged HRI/K199R was then immunoadsorbed with anti-His antibodies, and samples were analyzed for coadsorbing Hsp90,
Hsp70, and Cdc37 by SDS-PAGE and Western blotting. Lane 1: TnT lysate containing no plasmid as the control for nonspecific binding. Top panel:
autoradiogram of immunoadsorbed [35S]HRI/K199R. (B) [35S]His-tagged HRI was synthesized in reticulocyte lysate as described in the Experimental
Section. After 20 min, DMSO (4% v/v, lanes 1, 2, and 3), geldanamycin (3, 80 μM, lane 4), sodium molybdate (20 mM, lane 5), celastrol (2, 100 μM,
lane 6), novobiocin (4, 4.0 mM, lane 7), coumermycin A1 (5, 400 μM, lane 8), or 1 (50 μM, lane 9) was added, followed by an additional 10 min of
incubation. An aliquot of the TnT lysate was then transferred to hemin-supplemented (20 μM, lane 2) or heme-deficient (lanes 1 and 312) lysate
containing an equivalent concentration of each addition, followed by an additional 45 min of incubation. The samples were then analyzed for HRI
maturation by SDS-PAGE and autoradiography as described in the Experimental Section. Lane 1: TnT lysate containing no plasmid. [35S]HRI*: mature,
active HRI. (C) [35S]His-tagged HRI was synthesized in reticulocyte lysate and treated with DMSO or Hsp90 inhibitors as described above. Aliquots of
each reaction were taken prior to (upper panel, 0 min) and 45 min after (lower panel, 45 min) dilution into and incubation in heme-supplemented (lane 1) or
heme-deficient (lanes 28) lysate. The band intensities in the lower panel were quantified by scanning densitometry, and values below the lane numbers
are given as %OD/mm2 of minus heme control.
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buffer, with geldanamycin (3) having no significant effect on the
measured ka and kd or the calculatedKd (Table 1). Thus, the data
indicate that gambogic acid binds to the N-terminal domain of
Hsp90, and, like celastrol,11 it binds to a site distinct from the
ATP binding pocket. In addition, the Kd for the binding of 1 to
Hsp90 correlated well with the IC50 values for gambogic acid
(1)-induced inhibition of other Hsp90-dependent processes,
further supporting Hsp90 as one of the physiological targets of
this compound.
Virtual Docking of Gambogic Acid (1) to Hsp90NT. We
approached the problem of identifying the putative binding site
of gambogic acid (1) in the N-terminal domain of Hsp90 using
the “blind” docking method,33 in which the entire Hsp90
N-terminal domain, not just the geldanamycin-binding site,
was used to search for the lowest possible binding energy for 1.
The apo- and geldanamycin-bound Hsp90NT crystal structure,
PDB ID 1YET, along with the open or unbound crystal structure
of the Hsp90NT, PDB ID 1YES, were used for docking of 1 to
determine if it would compete for the geldanamycin-binding site
or bind elsewhere. These two structures share a 0.25 Å rmsd of
the CR backbone spanning the entire 221 residues of the crystal
structures with the majority of conformational changes occurring
in residues 105112.34 In all three docking experiments, 1
preferentially bound to the cleft created by R-helix 9 (H9) and
β-sheet strand 8 (S8), residues 200222 (Figure 5A) that are
composed of both hydrophobic and positively charged elements
(Figure 5B). The calculated average binding affinities for 1 for
this region were9.44,9.50, and9.37 kcal/mol for the apo-
and geldanamycin-bound and open structures, respectively.
Docking results predict that aliphatic hydrophobic interactions
would occur between the gambogic acid substituent arms and the
aliphatic side chains of H9 and Phe213 in the intervening loop,
while the xanthenone moiety would lie on the CR backbone of
S8, making a potential π interaction with the carbonyl and amide
bonds (Figure 5A). In addition, there is a potential salt bridge
between Lys208 of H9 and both oxygens of the carboxylic acid
moiety of 1, and a hydrogen bond between Lys204 of H9 and the
carbonyl moiety of the cyclohexene ring (Figure 5C). The
regions of H9 and S8 undergo minor conformational changes
with a 0.15 Å rmsd of the CR residues between residues
200222.
The docking results are consistent with gambogic acid (1)
being a noncompetitive inhibitor of the Hsp90 N-terminal
domain. The region of H9 and S8 of the HSP90 N-terminal
domain undergoes little change between the geldanamycin-
bound structure and the open conformation structure with a
0.15 Å rmsd of the CR backbone of residues 200222. It should
be noted that this site is distinct from that previously proposed
for the binding of celastrol (2) to the Hsp90s N-terminal
domain.12
Recently, the combination of gambogic acid (1) and celastrol
(2) was reported to have a synergistic antitumor effect,35 an
observation that supports the notion that the two compounds
interact with different sites within the N-terminal domain of
Figure 4. SPR analysis of the interaction of gambogic acid (1) with (A)
full-length Hsp90 and (B) the N-terminal domain of Hsp90. (A)
Injection of 1.0, 10, 25, and 50 μM 1 over a SPR chip containing bound
full-length Hsp90. (B) Injection of 0.5, 5, 15, and 25 μM 1 over a SPR
chip containing boundHsp90NT. Black line: sensorgram of binding and
dissociation; gray line with dots: curve fit.
Table 1. Constants for the Binding of Gambogic Acid (1) to
Hsp90
protein ka (M
1 s1) kd (s
1) KD (μM)
full-length Hsp90 1.16(8)  103 0.0113(4) 9.8(2)
Hsp90NT 1.47(6)  103 0.01122(7) 7.6(3)
Hsp90NT (þ20 μM GA) 1.62(8)  103 0.0114(7) 7.0(4)
Hsp90CT no binding
Figure 5. Models of gambogic acid (1) docked to geldanamycin-bound
Hsp90NT. (A) Ribbon diagram of Hsp90NT with the carbons of 1 and
geldanamycin shown in yellow and green, respectively. (B) Electrostatic
surface potential of Hsp90NT shown in the same orientation as in A. (C)
Close-up showing the salt bridge andH-bond formed between K208 and
K204 with 1.
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Hsp90. The question of whether combinations of Hsp90 in-
hibitors that act by different mechanisms will demonstrate similar
synergistic effects on cancer cell growth has yet to be explored,
but the synergy exhibited by 1 and 2 suggests that such studies
would be productive. For example, the ability of C-terminal
inhibitors, such as novobiocin, to block the activation of HSF136
may potentiate the cytoxicity of N-terminal inhibitors of Hsp90,
which induce heat shock protein expression.
Conclusion. The data presented above firmly establish gam-
bogic acid (1) as an inhibitor of Hsp90 and provide evidence of a
new site that can be targeted for the development of improved
Hsp90 inhibitors. Previous work with 1 has indicated that it
reduces the activity or the levels of expression of well-known
Hsp90-dependent clients (see: http://www.picard.ch/down-
loads/Hsp90interactors.pdf and http://www.picard.ch/down-
loads/Hsp90facts.pdf) that are involved in the regulation of
cell immortality (telomerase),37,38 cell growth (Akt, cSrc, Cdk2,
and Cdk4),3941 apoptosis (Bcl-2, Bcl-xL, and survivin),4244
angiogenesis (VEGFR),40,41 and metastasis (MMP2 and
MMP9).22,45 Changes in levels of expression of proteins (Bcl-
2, Bcl-xL, survivin, and telomerase) appeared to occur primarily
at the level of transcription rather than through destabilization of
the protein, as mRNA levels coding for the protein were
decreased. These changes, however, can still be accounted for
by a mechanism invoking gambogic acid-induced inhibition of
Hsp90, as NF-κB regulates the expression of Bcl-2, Bcl-xL, and
survivin, as well as VEGF,17,22 and NF-κB activation is well
known to be regulated by Hsp90.46 This notion is supported by
the observations that the Hsp90 inhibitor geldanamycin (3)
inhibits the expression of Bcl-2 and Bcl-xL by suppressing the
activation of NF-κB47 and has the same effects as gambogic acid
on VEGFR signaling.48,49 Furthermore, telomerase expression is
regulated by c-Myc, and Hsp90 inhibition has recently been
demonstrated to destabilize c-Myc,50 in addition to blocking the
interaction of Hsp90 with the telomerase promoter, which
suppresses telomerase expression.51 While this article was in
preparation, gambogic acid (1) was confirmed to block NF-κB
activation through its ability to inhibit Hsp90.52 Thus, many of
the physiological effects of 1 on cultured cells reported previously
in the literature can be accounted for, in part, by its ability to
inhibit Hsp90 function.
’EXPERIMENTAL SECTION
Screen for Inhibitors of Hsp90-Dependent Luciferase
Refolding. Natural product libraries from Microsource and Biomol
were screened as previously described for inhibitors of Hsp90-depen-
dent refolding of thermally denatured firefly luciferase.53 Positive hits
were then screened against native luciferase to eliminate false positives
that were direct inhibitors of luciferase. Subsequently, celastrol (2,
CalBiochem 219465, g95% by TLC) and gambogic acid (1, Biomol
BML-AP305, 98% by TLC) were titrated into reticulocyte lysate
containing thermally denatured luciferase to determine the concentra-
tion of test compound required to inhibit luciferase refolding by 50%
(IC50) compared to the DMSO control, as previously described.
54
Reactions were carried out in triplicate at room temperature in 96-well
microtiter plates, and experiments were repeated at least twice, with
relative light unit (RLU) production measured using a LMaxII
(Molecular Devices) microplate reader and a 10 s integration time.54
Effect of Gambogic Acid (1) on Cell Proliferation. MCF-7
and HeLa cells were grown in Gibco modified essential medium,
supplemented with nonessential amino acids, 2 mM glutamine, and
10% fetal bovine serum. SkBr3 cells were maintained in DMEM/F12
(1:1) medium (Gibco) with L-glutamine supplemented with strepto-
mycin (500 μg/mL), penicillin (100 units/mL), and 10% fetal bovine
serum. Cells were grown to confluence in a humidified atmosphere
(37 C, 5% CO2). Cells were seeded at 2000 cells per well in a clear 96-
well plate, the medium volume was brought to 100 μL, and the cells
were allowed to attach overnight. The next day, varying concentrations
of compound or 1% DMSO vehicle control was added to the wells.
Cells were then incubated at 37 C for 72 h. Cell viability was
determined using the Promega Cell Titer 96 Aqueous One Solution
cell proliferation assay. After incubation with compounds, 20 μL of the
assay substrate solution was added to the wells, and the plate was
incubated at 37 C for an additional 1 h. Absorbance at 490 nm was
then read on a Molecular Devices Versamax plate reader, and values
were expressed as percent of absorbance from cells incubated in
DMSO alone.
Effect of Gambogic Acid (1) on the Interaction of Hsp90
and Its Co-chaperones with Heme-Regulated eIF2R Kinase
(HRI).His-tagged kinase-dead HRI/K199R was synthesized by coupled
transcriptiontranslation (TnT) in reticulocyte lysate in the presence of
[35S]methionine.55,56 After 20 min of synthesis, compounds or an
equivalent volume of DMSO or water was added at the concentrations
indicated in the figure legend, and synthesis was continued for an
additional 10 min. Subsequently, aliquots were taken for immunoad-
sorption of His-tagged HRI with anti-His-tag antibodies bound to anti-
mouse-IgG agarose resin.55,56 Agarose resins containing bound anti-His-
tag antibody were washed four times with 10mMPIPES (pH = 7.2) plus
100 mM NaCl and analyzed by SDS-PAGE and Western blotting for
coadsorbed Hsp90, Hsp70, and Cdc37, as previously described.55,56
Lysate lacking plasmid encoding His-tagged HRI was used as the control
for nonspecific binding.
Effect of Gambogic Acid (1) on Hsp90-Dependent HRI
Maturation/Activation. [35S]His-tagged wild-type HRI or K199R
mutant was generated by TnT in reticulocyte lysate, as described above.
After 30 min, samples were diluted into 7 volumes of hemin-supple-
mented or heme-deficient lysate containing DMSO, water, or test
compound at the same concentration present in the TnT lysate and
incubated for an additional 45 min.55,56 The His-tagged HRI was
adsorbed from samples by the addition of NTA-Ni resin on ice for 1 h.
Resins were washed and eluted by boiling in SDS-sample buffer, and
samples were analyzed by SDS-PAGE and autoradiography after elec-
trotransfer to PVDF membrane to detect a shift in the electrophoretic
mobility of HRI, which is dependent upon its Hsp90-dependent
maturation/activation.55,56
Gambogic Acid (1)-Induced Depletion of Hsp90-Depen-
dent Proteins from Cultured MCF7 and SKBr3 Breast Cancer
and HeLa Cells. MCF-7, SkBr3, and HeLa cells were grown to
confluence as described above, seeded in culture dishes (1 106/dish),
and allowed to attach overnight. Gambogic acid (1) was added at the
concentrations indicated in Figure 1, and the cells were incubated for an
additional 36 h. Cells were harvested and analyzed for Hsp90 client
protein degradation (Her2, Raf-1, and Akt) and heat shock protein
induction (Hsp90 and Hsp70), as described previously.57 For compar-
ison, cells were incubated with DMSO (1%) or geldanamycin
(3, 500 nM), and extracts (10 μg of protein) were Western blotted
for the indicated proteins with actin used as the loading control. One
microgram of SkBr3 extracts was used for the Western blot for Her2.
Surface Plasmon Resonance Spectroscopy of Gambogic
Acid (1) Binding to Hsp90. Insect Sf9 cells overexpressing human
Hsp90β were cultured and harvested by the Baculovirus/Monoclonal
Antibody Core Facility at Baylor College of Medicine. Hsp90β was
extracted and purified (>98% pure) as described previously,58,59 but
without the initial DEAE-cellulose chromatography step. Bacterial E. coli
DE-3 Star cells carrying plasmids for the expression of either the
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N-terminal (Hsp90NT: amino acids 1241 with a C-terminal
GELRSGC tail) or C-terminal (Hsp90CT: amino acids 531732)
domains of Hsp90 were cultured in LBmedium and induced with IPTG.
Recombinant Hsp90NT and Hsp90CT were purified using a NiNTA
column. Following elution of the protein from the NiNTA column, the
N-terminal His-tag was cleaved using TEV protease (Invitrogen),
followed by size-exclusion chromatography on Superdex 200. The
Hsp90-containing fractions were pooled, concentrated, dialyzed against
10mMHepes (pH 7.5) containing 150mMNaCl and 10% glycerol, and
stored at 80 C until use. Prior to the use of the Hsp90NT or
Hsp90CT, each protein was reacted according to the manufacture’s
recommended protocol with the EZ-Link Maleimide-PEG2-Biotin
(Thermo Scientific) then buffer-exchanged into fresh 10 mM Hepes
(pH 7.5) containing 150 mM NaCl to eliminate free biotin entities.
The surface of a SSO1 CO2H SPR sensor chip mounted in a SensiQ
SPR instrument (ICX Nomadics) was activated by treatment withN0-3-
dimethylaminopropyl-N0-ethylcarbodiimide hydrochloride and N-hy-
droxysuccinimide for preferential cross-linking of full-length Hsp90s
N-terminus to the surface. For immobilization of Hsp90, 250 μL of
Hsp90 (6.2 mg/mL) in 10 mM Hepes buffer (pH 7.4) containing
150mMNaCl was injected at a flow rate of 10 μL/min, resulting in 2000
response units of protein captured on the experimental surface of the
chip. Then, 1M ethanolamine (pH 8) was used to quench the remaining
activated groups, and the surface washed with buffer containing 10 mM
PIPES pH 7.4, 300 mM NaCl, and 2% DMSO. The surface of a SSO3
BioCap SPR sensor chip wasmounted in a SensiQ SPR instrument (ICX
Nomadics), and either the biotinylated Hsp90NT (7.0 mg/mL) or
Hsp90CT (6.8 mg/mL) was discrete-injected over the experimental
channel at a flow rate of 10 μL/min, resulting in capture of Hsp90NT at
1400 response units and Hsp90CT at 1250 response units of protein on
the experimental surface of the chip. The chips were then washed with
assay buffer prior to experimental analysis.
Gambogic acid (1) was diluted in assay buffer containing 10 mM
PIPES pH 7.4, 300 mM NaCl, and 2% DMSO and injected over the
surface of each derivatized chip at a flow rate of 15 μL/min at 25 C at the
indicated concentrations. Additionally, for competition studies 1 was
diluted in assay buffer containing 20 μM geldanamycin (3). All measure-
ments were done in triplicate. SPR binding curves were analyzed using
QDAT software (ICX Nomadics) to calculate the ka, kd, and KD data.
Docking Studies of Geldanamycin (3) and Gambogic Acid
(1) with the N-Terminal Domain of Hsp90. In silico docking of
geldanamycin and gambogic acid with the 3D coordinates of the X-ray
crystal structures of the N-terminal domain of HSP90 with bound 3 and
in the open conformation, PDB IDs 1YET and 1YES, respectively, was
accomplished using the AutoDock program60 downloaded from the
Molecular Graphics Laboratory of the Scripps Research Institute. The
AutoDock program was chosen because it uses a genetic algorithm to
generate the poses of the ligand inside a known or predicted binding site
utilizing the Lamarckian version of the genetic algorithm where the
changes in conformations adopted by molecules after in situ optimiza-
tion are used as subsequent poses for the offspring.
In the docking experiments carried out, water was removed from the
3D X-ray coordinates while Gasteiger charges were placed on the X-ray
structures of the N-terminal domain of HSP90 along with geldanamycin
(3) and 1 using tools from the AutoDock suite. A grid box centered on
the N-terminal HSP90 domain with definitions of 126  126  126
points and 0.4 Å spacing was chosen for ligand docking experiments.
The docking parameters consisted of setting the population size to 300,
the number of generations to 27 000, and the number of evaluations to
20 000 000, while the number of docking runs was set to 50 with a cutoff
of 1 Å for the root-mean-square tolerance for the grouping of each
docking run.
While the binding mode of geldanamycin with Hsp90 has been
determined through X-ray crystallography,34 the binding mode of 1with
Hsp90 has yet to be determined through either NMR spectroscopy or
X-ray crystallography. The docking of geldanamycin to the apo X-ray
structure of Hsp90NT, PDB ID 1YET, was used as a control to test and
validate the docking parameters used. As expected, geldanamycin (3)
docked to the binding site identified in the crystal structure with an
average binding energy of9.65 kcal/mol and a 1 Å average root-mean-
square deviation from the reference structure.
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